文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Engaging patients in medicines regulation: a tale of two agencies.

作者信息

Mavris Maria, Furia Helms Andrea, Bere Nathalie

出版信息

Nat Rev Drug Discov. 2019 Nov;18(12):885-886. doi: 10.1038/d41573-019-00164-y.

DOI:10.1038/d41573-019-00164-y
PMID:31780842
Abstract
摘要

相似文献

[1]
Engaging patients in medicines regulation: a tale of two agencies.

Nat Rev Drug Discov. 2019-11

[2]
Multistakeholder Advice at the European Medicines Agency: Is It Still Needed?

Clin Pharmacol Ther. 2019-4

[3]
European Medicines Agency pledges to publish clinical reports.

BMJ. 2014-10-7

[4]
Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.

Clin Med (Lond). 2006

[5]
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.

Eur J Clin Pharmacol. 2002-11

[6]
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

Int J Cancer. 2018-1-15

[7]
Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?

Clin Pharmacol Ther. 2019-10-24

[8]
The US Food and Drug Administration-European Medicines Agency collaboration in pharmacovigilance: common objectives and common challenges.

Drug Saf. 2015-1

[9]
Consumer understanding of the scope of FDA's prescription drug regulatory oversight: A nationally representative survey.

Pharmacoepidemiol Drug Saf. 2020-2

[10]
European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective.

Clin Pharmacol Ther. 2019-4

引用本文的文献

[1]
Characterising meaningful patient and public involvement in the pharmaceutical industry research setting: a retrospective quality assessment.

BMJ Open. 2023-8-23

[2]
Comparison of published core outcome sets with outcomes recommended in regulatory guidance from the US Food and Drug Administration and European Medicines Agency: cross sectional analysis.

BMJ Med. 2022-11-3

[3]
Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes.

Diabetes Care. 2022-10-1

[4]
Practices of patient engagement in drug development: a systematic scoping review.

Res Involv Engagem. 2022-6-29

[5]
Patient-Centered Core Impact Sets: What They are and Why We Need Them.

Patient. 2022-11

[6]
Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases.

Ther Innov Regul Sci. 2022-11

[7]
Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance.

Trials. 2022-1-15

[8]
Co-creation of practical "how-to guides" for patient engagement in key phases of medicines development-from theory to implementation.

Res Involv Engagem. 2021-8-23

[9]
Translational precision medicine: an industry perspective.

J Transl Med. 2021-6-5

[10]
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.

Ther Innov Regul Sci. 2021-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索